Table 3.

Association between baseline biomarker values and TNFi treatment response in patients with psoriatic arthritis.

Biomarker	Univariate Model			Multivariate Model
				Full Model			Reduced Model
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
MMP-3	1.067	1.002, 1.138	0.045	1.170	1.001, 1.367	0.048	1.067	1.002, 1.138	0.045
COMP	0.969	0.836, 1.123	0.678	0.678	0.453, 1.017	0.060
hsCRP	1.233	0.995, 1.528	0.056	1.295	0.863, 1.945	0.212
RANKL	1.000	0.995, 1.005	0.984	1.008	0.997, 1.020	0.155
OPG	1.002	0.997, 1.007	0.506	1.004	0.993, 1.016	0.476
RANKL:OPG	0.699	0.082, 5.996	0.744
TNFSF14	1.005	0.999, 1.012	0.131	1.002	0.99, 1.015	0.699
CS-846	0.995	0.977, 1.013	0.584	0.978	0.949, 1.007	0.134
C1-2C	0.017	0.000, 6.026	0.174
CPII	1.002	0.998, 1.006	0.394	1.011	0.999, 1.022	0.065
C2C	1.001	0.985, 1.017	0.891	0.967	0.921, 1.016	0.187
CPII:C2C	1.516	0.609, 3.775	0.372

Odds ratios (OR) reflect the effect of having a 1-unit higher value of each biomarker, except for COMP (100-unit higher value); for abbreviations see Table 2.